Bristol-Myers Squibb BMY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.68B+8.8% | $1.09B— | $2.2B+80.7% | $1.31B-22.0% | $2.46B+121% | ||
| $594M-41.3% | $977M-48.0% | $1.01B-61.0% | $1.01B-61.1% | $1.01B-60.0% | ||
| $146M+1.4% | $133M+10.8% | $139M+7.8% | $137M+9.6% | $144M+8.3% | ||
| $161M-27.8% | -$392M+50.4% | -$359M-40.2% | -$437M-32.0% | $223M+131% | ||
| -$14M-108% | —— | $90M-58.7% | —— | $169M-22.5% | ||
| $409M+581% | -$90M-117% | $160M+143% | —— | -$85M-128% | ||
| $1.64B+54.5% | -$1.07B-47.3% | —— | —— | $1.06B+74.2% | ||
| $187M+246% | -$324M— | $887M+355% | -$621M+68.0% | $54M-94.1% | ||
| -$1.69B-11,147% | —— | —— | $484M-52.5% | -$15M+96.9% | ||
| $1.1B-43.5% | $1.97B-55.5% | $6.31B+12.9% | $3.92B+68.4% | $1.95B-31.1% | ||
| $347M+33.5% | $370M-2.1% | $320M-1.2% | $361M+37.8% | $260M-8.5% | ||
| $65M-16.7% | $1.71B+3,532% | $1.87B+439% | $285M-79.2% | $78M-99.6% | ||
| -$131M+73.7% | -$1.46B-644% | -$1.7B-677% | -$473M+64.1% | -$499M+97.5% | ||
| $1.28B+2.0% | $1.26B+3.6% | $1.26B+3.9% | $1.26B+3.7% | $1.26B+3.8% | ||
| $500M— | $10.07B— | $229M-90.8% | $643M+62.8% | $0— | ||
| -$1.56B-57.1% | -$6.03B— | -$1.49B— | -$1.84B— | -$993M-107% | ||
| -$48M-173% | $5M+103% | $0-100% | $128M+682% | $66M+247% | ||
| -$635M-220% | -$5.51B— | $3.12B— | $1.74B+157% | $528M+124% | ||
| $94M-50.0% | $1.39B+4,543% | $633M+142% | $1.51B+1,042% | $188M-98.5% | ||
| —— | $15M— | $0— | $336M— | $0— | ||
| $34M-88.4% | —— | —— | —— | $292M+4.4% | ||
| $412M+8,140% | $584M-70.1% | $196M+41.0% | $313M-64.0% | $5M+400% | ||
| -$3.5B-457% | -$2.4B— | $1.7B-6.4% | $881M+19.9% | -$627M+5.7% | ||
| -$21M-320% | -$308M— | $74M+172% | $7M— | -$5M+78.3% | ||
| $312M+28.4% | —— | —— | —— | $243M-11.6% | ||
| $359M+63.2% | $402M+548% | $829M+248% | $524M+599% | $220M-70.5% | ||
| $391M+3,158% | $16M-92.2% | $49M— | $0-100% | $12M+140% | ||
| -$98M+4.9% | -$33M-73.7% | -$3M— | $0+100% | -$103M-6.2% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $321M-12.8% | —— | $5M-94.7% | $58M-82.2% | $368M+343% | ||
| —— | $0— | $0-100% | —— | —— | ||
| $757M-55.3% | $1.6B-60.5% | $5.99B+13.7% | $3.56B+72.3% | $1.69B-33.6% | ||
| $757M-55.3% | $1.6B-60.5% | $5.99B+13.7% | $3.56B+72.3% | $1.69B-33.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bristol-Myers Squibb generate?
- Bristol-Myers Squibb (BMY) generated $13.3B in operating cash flow over the trailing twelve months.
- What is Bristol-Myers Squibb's free cash flow?
- After $1.4B of capital expenditures, Bristol-Myers Squibb's free cash flow was $11.9B over the trailing twelve months, down 9.0% year over year.
- Where does Bristol-Myers Squibb's cash flow data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
